Evidence map›Paper›PMID 42620948›Full record

ArticleFrontiers in aging neuroscience2026

Alzheimer's disease polygenic risk score associates with hippocampal subfield atrophy and immune-related genetic mechanism.

Clàudia Olivé, Itziar de Rojas, Linda Zhang, Oscar Sotolongo-Grau, Inés Quintela, Pablo García-González, Raquel Puerta, Laura Montrreal, Paula Bayón, Marta Rovira and 23 more

Abstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Clàudia OlivéAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Itziar de RojasAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Linda ZhangAlzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, Madrid, Spain.
Oscar Sotolongo-GrauAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Inés QuintelaGrupo de Medicina Xenómica, Centro Nacional de Genotipado (CEGEN-PRB3-ISCIII), Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
Pablo García-GonzálezAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Raquel PuertaAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Laura MontrrealAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Paula BayónAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Marta RoviraAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Alejandro ValenzuelaAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Maria Capdevila-BayoAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Álvaro MuñozAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Andrea MiguelAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Berta CalmAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Miguel CaleroCIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
Alberto RábanoCIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
Ana Belén PastorAlzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, Madrid, Spain.
Teodoro Del SerAlzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, Madrid, Spain.
Miguel MedinaCIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
Ángel CarracedoGrupo de Medicina Xenómica, Centro Nacional de Genotipado (CEGEN-PRB3-ISCIII), Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
Alfredo RamírezDivision of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Laura Molina-PorcelAlzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, I Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS) and Institute of Neurosciences, University of Barcelona, Barcelona, Spain.
Xavier MontalbánAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Amanda CanoAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Sergi ValeroAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Marta MarquiéAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Pilar SanzAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Pascual Sánchez-JuanCIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain.
Mercè BoadaAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Bryan StrangeLaboratory for Clinical Neuroscience, Centre for Biomedical Technology, Universidad Politécnica de Madrid, IdISSC, C. del Prof Martín Lagos, Madrid, Spain.
Maria Victoria FernándezAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.
Agustín RuizAce Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hippocampal atrophy is frequently observed in neurodegenerative diseases such as Alzheimer's disease (AD) or hippocampal sclerosis of aging (HS-aging). Volume loss in the hippocampus is described as prodromal stage of dementia and has been associated with AD polygenic risk score (PRS). CA1 and subiculum atrophy have been suggested to be a promising Materials and methods: We used regression models to assess the relation of the AD-PRS, and genome-wide significant AD variants, with CA1 and subiculum volumes assessed by magnetic resonance imaging (MRI) in 1,859 participants without dementia (with mild cognitive impairment or cognitively healthy). Co-regulatory network analyses and over-representation enrichment analyses were conducted to identify biological pathways enriched with co-regulatory networks of genes associated with hippocampal subregion volumes. We meta-analyzed data from seven cohorts to associate their AD-PRS with AD in the presence of concomitant brain pathologies. Results: Reduced volumes of CA1 and subiculum show association with higher levels of AD-PRS and with variant rs5848 in Discussion: Specific AD-SNPs enriched in immune-brain axis pathways rather than A

Indexed as

Alzheimer’s diseasehippocampal sclerosis of aginghippocampal subfield volumesmagnetic resonance imagingpolygenic risk score

Identifiers

PMID42620948
PMCPMC13485868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.